Similar articles

• Conventional and molecular epidemiology of trimethoprim-sulfamethoxazole resistance among urinary Escherichia coli isolates.

  Burman WJ, Breese PE, Murray BE, Singh KV, Batal HA, MacKenzie TD, Ogle JW, Wilson ML, Reves RR, Mehler PS. Burman WJ, et al. Am J Med. 2003 Oct 1;115(5):358-64. doi: 10.1016/s0002-9343(03)00372-3. Am J Med. 2003. PMID: 14553870
• Increasing in vitro resistance of E coli to TMP/SMX.

  [No authors listed] [No authors listed] Postgrad Med. 2001 Aug;110(2 Suppl):5-8; discussion 26-7. doi: 10.3810/pgm.08.2001.suppl15.80. Postgrad Med. 2001. PMID: 19667569 No abstract available.
• The role of clinical guidelines.

  [No authors listed] [No authors listed] Postgrad Med. 2001 Aug;110(2 Suppl):16-20; discussion 26-7. doi: 10.3810/pgm.08.2001.suppl15.83. Postgrad Med. 2001. PMID: 19667572 No abstract available.
• [Present status of the treatment of urological infections].

  Ukhin AV. Ukhin AV. Antibiot Med Biotekhnol. 1985 May;30(5):384-91. Antibiot Med Biotekhnol. 1985. PMID: 3896135 Review. Russian. No abstract available.
• The comeback of trimethoprim in France.

  Caron F, Wehrle V, Etienne M. Caron F, et al. Med Mal Infect. 2017 Jun;47(4):253-260. doi: 10.1016/j.medmal.2016.12.001. Epub 2017 Jan 2. Med Mal Infect. 2017. PMID: 28043762 Review.